Imbria Presents Positive Clinical Data from Phase 2 IMPROVE-DiCE Trial of Ninerafaxstat in Patients with Cardiometabolic HFpEF at ACC.25

March 29, 2025 Imbria Presents Positive Clinical Data from Phase 2 IMPROVE-DiCE Trial of Ninerafaxstat in Patients with Cardiometabolic HFpEF at ACC.25 Ninerafaxstat improves cardiac energetics, cardiac reserve capacity, 6-minute walk distance and heart failure-related health status (KCCQ) in cardiometabolic HFpEF Findings support further development of ninerafaxstat in HFpEF and adjacent CV indications such […] The post Imbria Presents Positive Clinical Data from Phase 2 IMPROVE-DiCE Trial of Ninerafaxstat in Patients with Cardiometabolic HFpEF at ACC.25 appeared first on Imbria .